FDA approves Faslodex (fulvestrant) 500mg as expanded use for postmenopausal women with HR+/HER2- advanced breast cancer.-AstraZeneca
AstraZeneca announced that the FDA has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, who have gone through menopause and have not received previous endocrine therapy. The FDA approval is based on data from the Phase III FALCON trial, which were published in the November 2016 issue of The Lancet.
The FALCON trial was designed to demonstrate superiority and included 462 postmenopausal women with HR+ metastatic or locally-advanced breast cancer. The results showed a statistically-significant increase in investigator-assessed median progression-free survival (PFS), representing a 20% reduction in the risk of disease progression or death – median PFS of 16.6 months in patients who received Faslodex, compared to 13.8 months in patients receiving the aromatase inhibitor anastrozole 1mg (HR: 0.797; 95% CI: 0.637-0.999; p=0.049).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins